Craft
ObsEva

ObsEva

Total Funding

$92.9 M

ObsEva Summary

Company summary

Overview
Innovating Women’s Reproductive Health and Pregnancy Therapeutics ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics.
Type
Private
Founded
2012
HQ
Plan-les-Ouates, CH | view all locations
Website
http://www.obseva.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Ernest Loumaye

    Ernest Loumaye, Co-Founder, Director

  • Jean-Pierre Gotteland

    Jean-Pierre Gotteland, Chief Scientific Officer and Head of R&D

  • Ed Mathers

    Ed Mathers, Director

    • Clive Bertram

      Clive Bertram, Chief Commercial Officer

      LocationsView all

      3 locations detected

      • Plan-les-Ouates, GE HQ

        Switzerland

        Chemin des Aulx 12

      • Boston, MA

        United States

        675 Atlantic Ave 2nd floor

      • Sacramento, CA

        United States

        400 R St

      Footer menu